Xlear Nasal Decongestant

Description

No description information is available.

Uses and Indications

This drug is indicated for use in individuals aged 6 years and older, with adult supervision required for those under 18. The recommended dosage is 1-2 sprays in each nostril, administered no more frequently than every 10 to 12 hours. The total dosage should not exceed 2 doses within a 24-hour period.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The product should be shaken well before use to ensure proper dispersion of the formulation. Prior to administration, the nasal passageway should be cleared by gently blowing the nose. For initial use, the cap must be removed, and the pump should be primed by holding it upright and pumping one or more times until the solution is dispensed.

For patients aged 6 years and older, including adults (with appropriate adult supervision), the recommended dosage is 1 to 2 sprays in each nostril. This can be repeated not more frequently than every 10 to 12 hours. It is important not to exceed 2 doses within a 24-hour period.

To administer, the nozzle should be inserted into the nostril, and the pump must be depressed completely while the patient inhales through the nose. After use, the nozzle should be cleaned to maintain hygiene and ensure proper function of the device.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

The use of this container by more than one individual may facilitate the transmission of infections; therefore, it is imperative to restrict its use to a single person. To ensure safety, the product must be kept out of reach of children.

Healthcare professionals should advise patients to clean the nozzle after each use and securely replace the cap to maintain hygiene and prevent contamination. It is crucial not to exceed the recommended dosage, as doing so may lead to adverse effects. Additionally, this product should not be utilized for more than three consecutive days without consulting a healthcare provider.

For individuals who are pregnant or breastfeeding, it is essential to seek guidance from a health professional prior to use. Furthermore, patients should be encouraged to consult a physician before using this product if they have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, or difficulty urinating due to an enlarged prostate gland.

This product is not intended for use in children under the age of six unless specifically directed by a physician.

Side Effects

Patients using this product may experience a range of adverse reactions, which can be categorized based on their seriousness and frequency.

Serious adverse reactions include the potential for infection transmission due to the use of the container by more than one person. It is crucial for patients to adhere to the recommended guidelines, including keeping the product out of reach of children and ensuring the nozzle is cleaned after each use. Additionally, patients should not exceed the recommended dosage or use the product for more than three days without consulting a healthcare professional.

Patients who are pregnant or breastfeeding are advised to seek guidance from a health professional prior to using this product. Furthermore, individuals with pre-existing conditions such as heart disease, high blood pressure, thyroid disease, diabetes, or those experiencing difficulty urinating due to an enlarged prostate gland should consult a physician before use.

This product is not intended for children under the age of six unless directed by a physician. Adherence to these warnings is essential to minimize the risk of adverse reactions and ensure safe usage.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Xlear Nasal Decongestant (nasal spray). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under the age of 6 should not use this medication unless directed by a physician. For children aged 6 years to adulthood, the recommended dosage is 1-2 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is important to note that the total dosage should not exceed 2 doses within a 24-hour period. Adult supervision is advised for patients in this age group to ensure proper administration and adherence to dosing guidelines.

Geriatric Use

Elderly patients may use this medication; however, it is not indicated for children under the age of 6 unless specifically directed by a physician. For patients aged 6 years and older, including adults, the recommended dosage is 1-2 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is crucial that patients do not exceed 2 doses within a 24-hour period.

Healthcare providers should exercise caution when prescribing this medication to geriatric patients, ensuring that they are monitored for any potential adverse effects or complications. Adjustments to the dosage regimen may be necessary based on individual patient response and tolerance.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure maternal and fetal safety.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential risks associated with excessive dosing of the medication.

Should an overdosage occur, it is recommended that healthcare providers assess the patient's clinical status and initiate appropriate monitoring. Symptoms of overdosage may vary depending on the medication involved and the individual patient's response.

Management procedures should include supportive care, which may involve symptomatic treatment and monitoring of vital signs. In cases where the specific antidote or treatment protocol is known, it should be administered as per established guidelines.

Healthcare professionals are encouraged to consult relevant toxicology resources or poison control centers for guidance on managing suspected overdosage cases effectively.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

Postmarketing experience has identified the following adverse reactions reported voluntarily or through surveillance programs: headache, nasal irritation, and sneezing. These events have been documented in the context of routine pharmacovigilance activities.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion or misuse. It is important to emphasize the necessity of proper storage to ensure the safety of young individuals.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light exposure to protect its quality. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered via the nasal route, suitable for patients aged 6 years and older, with adult supervision recommended. The dosing regimen involves spraying 1-2 times in each nostril, not to exceed every 10 to 12 hours, and a maximum of 2 doses within a 24-hour period.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Xlear Nasal Decongestant, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)